EP 4149947 A1 20230322 - SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN
Title (en)
SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN
Title (de)
SPIROSULFONAMIDDERIVATE ALS INHIBITOREN DES PROTEINS MYELOISCHER ZELLLEUKÄMIE-1 (MCL-1)
Title (fr)
DÉRIVÉS DE SPIRO-SULFONAMIDE UTILISÉS EN TANT QU'INHIBITEURS DE LA PROTÉINE DE LA LEUCÉMIE MYÉLOÏDE-1 (MCL-1)
Publication
Application
Priority
- US 202063024110 P 20200513
- US 2021032263 W 20210513
Abstract (en)
[origin: WO2021231737A1] The disclosure is directed to crystalline forms of the compound of Formula I: Formula (I), and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.
IPC 8 full level
C07D 515/04 (2006.01); A61P 35/00 (2006.01)
CPC (source: EP IL KR US)
A61K 31/553 (2013.01 - KR); A61P 35/00 (2017.12 - EP IL KR US); C07D 515/04 (2013.01 - EP IL KR); C07D 515/10 (2013.01 - US); C07B 2200/13 (2013.01 - KR US)
Citation (search report)
See references of WO 2021231737A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2021231737 A1 20211118; AU 2021271694 A1 20230119; BR 112022022995 A2 20230117; CA 3183270 A1 20211118; CN 115698024 A 20230203; EP 4149947 A1 20230322; IL 298157 A 20230101; JP 2023526235 A 20230621; KR 20230024287 A 20230220; MX 2022014219 A 20230116; US 2023357275 A1 20231109
DOCDB simple family (application)
US 2021032263 W 20210513; AU 2021271694 A 20210513; BR 112022022995 A 20210513; CA 3183270 A 20210513; CN 202180042066 A 20210513; EP 21730723 A 20210513; IL 29815722 A 20221113; JP 2022568748 A 20210513; KR 20227043707 A 20210513; MX 2022014219 A 20210513; US 202117998518 A 20210513